Leriglitazone demonstrates lesion growth deceleration in pediatric cerebral adrenoleukodystrophy
Minoryx's leriglitazone showed a decrease in matrix metalloproteinase-9 concentrations in pediatric patients with cerebral adrenoleukodystrophy, according to a 24-week analysis.
FDA clears Theranica's Nerivio for migraine prevention in patients 12 and older
The wearable device received its original FDA go-ahead in 2019, and has since demonstrated effectiveness in preventive and acute care for migraine treatment in adolescents and adults.
New screening tool shows success in identifying movement disorders in patients with inborn errors of metabolism
Researchers designed a new screening tool to assist nonmovement disorders specialists with identifying involuntary movements in patients aged at least 4 years of age with an inborn error of metabolism.
2 Commerce Drive Cranbury, NJ 08512